Alpha Teknova Reports Revenue Growth and New Collaboration

Alpha Teknova, Inc. ( (TKNO) ) has released its Q1 earnings. Here is a breakdown of the information Alpha Teknova, Inc. presented to its investors.

Alpha Teknova, Inc., a prominent player in the life sciences sector, specializes in producing critical reagents for the development of novel therapies, vaccines, and molecular diagnostics. The company is known for its innovative solutions that support the discovery and commercialization of next-generation therapies.

In its first quarter of 2025, Alpha Teknova reported a revenue of $9.8 million, marking a 5% increase compared to the previous year. The company also introduced a new cryopreservation system, PluriFreeze, in collaboration with Pluristyx, Inc., further enhancing its cell therapy product portfolio.

Key financial highlights include a 12% increase in Lab Essentials revenue and a significant improvement in gross profit and margin, attributed to higher revenue and reduced overhead costs. Despite a net loss of $4.6 million, the company saw improvements in adjusted EBITDA and free cash flow compared to the previous year. Teknova’s collaboration with Pluristyx positions it as the exclusive distributor of the PluriFreeze system in North America.

Looking ahead, Teknova reaffirms its 2025 revenue guidance of $39-42 million and anticipates a full-year free cash outflow of less than $12 million. The company remains optimistic about its long-term growth, driven by its diverse customer base and the advancement of clinical therapies towards commercialization.